IL17A and inflammatory bowel disease: In a pooled analysis of clinical trials of IL-17 inhibitors, the association between secukinumab treatment and new-onset IBD was not observed (EAIR was 0.01–0.33/100 PY), which was comparable to the findings obtained for etanercept treatment [14,15].